ISSN: 2640-5601

Menu
  • Journal Home
  • Editorial Board
  • Articles
    • Online First
    • Current Issue
    • Archive
  • Guidelines
    • Author Guidelines
    • Peer Review Guidelines
  • Registrations
    • Reviewers
    • Editors
  • Submit Manuscript
  • Unsubscribe
  • Contact Us

Email: [email protected]

Volume 1 Isssue 1

Research Article: Lower Extremity Peripherals Arterial Disease Treatment

Wilbert S. Aronow*

In patients with PAD, smoking should be stopped and hypertension, dyslipidemia, and diabetes mellitus treated. Patients with PAD should be treated with atorvastatin 40 mg to 80 mg daily or rosuvastatin 20 to 40 mg daily.

ntiplatelet drugs such as aspirin or clopidogrel and angiotensin-converting enzyme inhibitors should be given .Beta blockers should be given if coronary artery disease, especially prior myocardial infarction, s present unless contraindicated. Cilostazol improves exercise time until intermittent claudication. Exercise rehabilitation programs should be used. Indications for lower extremity percutaneous transluminal angioplasty or bypass surgery are 1) incapacitating claudication in patients interfering with work or lifestyle; 2) limb salvage in patientss with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, and/or infection or gangrene; and 3) vasculogenic impotence.

Cite this Article: Aronow WS. Lower Extremity Peripherals Arterial Disease Treatment. SRL Vasc Med. 2016;1(1): 001-006.

Published: 04 January 2016

Submit ManuscriptSubmit Special Issue

Authors submit all Proposals and manuscripts via Electronic Form!

All Journals

SciRes Literature

  • Home
  • Open Access
  • Journals
  • Contact Us
  • Plagiarism Policy
Failed to connect to MySQL: Access denied for user 'sciresLiterature'@'localhost' (using password: YES)

Newsletter

Subscribe to our monthly Newsletter.

Get in touch

  • SciRes Literature
    1 E. Main St., Ste B, Middletown
    DE 19709, USA
    Email: [email protected]
    Tel: +302-684-6993
    Fax: +1-302-336-9808

Creative Commons License Open Access by SciRes Literature is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at www.sciresliterature.org.